References
Key articles
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-77.Full text Abstract
National Cancer Comprehensive Network. NCCN guidelines in oncology: acute myeloid leukemia [internet publication].Full text
Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jun;31(6):697-712.Full text Abstract
Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 Aug 11;4(15):3528-49.Full text Abstract
Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-43.Full text Abstract
Reference articles
1. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.Full text Abstract
2. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-28.Full text Abstract
3. Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015 May 21;125(21):3246-52.Full text Abstract
4. Bewersdorf JP, Zeidan AM. Hyperleukocytosis and leukostasis in acute myeloid leukemia: can a better understanding of the underlying molecular pathophysiology lead to novel treatments? Cells. 2020 Oct 17;9(10):2310.Full text Abstract
5. National Cancer Institute. Cancer stat facts: leukemia - acute myeloid leukemia (AML) [internet publication].Full text
6. Cancer Research UK. Acute myeloid leukaemia (AML) incidence statistics. Jul 2024 [internet publication].Full text
7. Hosing C, Munsell M, Yazji S, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar;13(3):450-9.Full text Abstract
8. Lenz G, Dreyling M, Schiegnitz E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol. 2004 Dec 15;22(24):4926-33. Abstract
9. Patel AA, Rojek AE, Drazer MW, et al. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 Oct 26;5(20):4140-8.Full text Abstract
10. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 1;102(1):43-52.Full text Abstract
11. Leone G, Pagano L, Ben-Yehuda D, et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007 Oct;92(10):1389-98.Full text Abstract
12. Pedersen-Bjergaard J, Christiansen DH, Andersen MK, et al. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia. 2002 Nov;16(11):2177-84. Abstract
13. Kayser S, Döhner K, Krauter J, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011 Feb 17;117(7):2137-45.Full text Abstract
14. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991 Dec 12;325(24):1682-7. Abstract
15. Qian Z, Joslin JM, Tennant TR, et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact. 2010 Mar 19;184(1-2):50-7.Full text Abstract
16. Maciejewski JP, Risitano A, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002 May 1;99(9):3129-35.Full text Abstract
17. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999 May 27;340(21):1649-60. Abstract
18. Berk PD, Wasserman LR, Fruchtman SM, et al. Treatment of polycythemia vera: a summary of trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia vera and the myeloproliferative disorders. Philadelphia, PA: WB Saunders; 1995:166-94.
19. Silverstein MN, Brown AL Jr, Linman JW. Idiopathic myeloid metaplasia. Its evolution into acute leukemia. Arch Intern Med. 1973 Nov;132(5):709-12. Abstract
20. Rosenthal S, Canellos GP, DeVita VT Jr, et al. Characteristics of blast crisis in chronic granulocytic leukemia. Blood. 1977 May;49(5):705-14. Abstract
21. Alter BP. Fanconi's anemia and malignancies. Am J Hematol. 1996 Oct;53(2):99-110. Abstract
22. Bloom G, Warner S, Gerald P, Diamond JK. Chromosomal abnormalities in constitutional aplastic anemia. N Engl J Med. 1966 Jan 6;274(1):8-14. Abstract
23. D'Andrea AD, Dahl N, Guinan EC, et al. Marrow failure. Hematology Am Soc Hematol Educ Program. 2002:58-72.Full text Abstract
24. Gilman PA, Jackson DP, Guild HG. Congenital agranulocytosis, prolonged survival and terminal acute leukemia. Blood. 1970 Nov;36(5):576-85. Abstract
25. Rosen RB, Kang SJ. Congenital agranulocytosis terminating in acute myelomonocytic leukemia. J Pediatr. 1979 Mar;94(3):406-8. Abstract
26. Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure syndromes. Br J Haematol. 2000 Oct;111(1):30-42. Abstract
27. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345-77.Full text Abstract
28. Taub JW, Berman JN, Hitzler JK, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017 Jun 22;129(25):3304-13.Full text Abstract
29. Jalbut MM, Sohani AR, Dal Cin P, et al. Acute myeloid leukemia in a patient with constitutional 47,XXY karyotype. Leuk Res Rep. 2015;4(1):28-30.Full text Abstract
30. Herold T, Metzeler KH, Vosberg S, et al. Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood. 2014 Aug 21;124(8):1304-11.Full text Abstract
31. Forestier E, Israeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008 Feb 1;111(3):1575-83. Abstract
32. Rinsky RA, Smith AB, Hornung R, et al. Benzene and leukemia. An epidemiologic risk assessment. N Engl J Med. 1987 Apr 23;316(17):1044-50. Abstract
33. Shallis RM, Weiss JJ, Deziel NC, et al. A clandestine culprit with critical consequences: benzene and acute myeloid leukemia. Blood Rev. 2021 May;47:100736. Abstract
34. Hayes RB, Yin SN, Doemeci M, et al. Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group. J Natl Cancer Inst. 1997 Jul 16;89(14):1065-71.Full text Abstract
35. Fircanis S, Merriam P, Khan N, et al. The relation between cigarette smoking and risk of acute myeloid leukemia: an updated meta-analysis of epidemiological studies. Am J Hematol. 2014 Aug;89(8):E125-32.Full text Abstract
36. Colamesta V, D'Aguanno S, Breccia M, et al. Do the smoking intensity and duration, the years since quitting, the methodological quality and the year of publication of the studies affect the results of the meta-analysis on cigarette smoking and Acute Myeloid Leukemia (AML) in adults? Crit Rev Oncol Hematol. 2016 Mar;99:376-88. Abstract
37. Mele A, Szklo M, Visani G, et al. Hair dye use and other risk factors for leukemia and pre-leukemia: a case control study. Italian Leukemia Study Group. Am J Epidemiol. 1994 Mar 15;139(6):609-19. Abstract
38. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: interview study from the Third National Cancer Survey. J Natl Cancer Inst. 1977 Mar;58(3):525-47. Abstract
39. Towle KM, Grespin ME, Monnot AD. Personal use of hair dyes and risk of leukemia: a systematic literature review and meta-analysis. Cancer Med. 2017 Oct;6(10):2471-86.Full text Abstract
40. Rota M, Porta L, Pelucchi C, et al. Alcohol drinking and risk of leukemia-a systematic review and meta-analysis of the dose-risk relation. Cancer Epidemiol. 2014 Aug;38(4):339-45. Abstract
41. Blair A, Zahm SH, Pearce NE, et al. Clues to cancer etiology from studies of farmers. Scand J Work Environ Health. 1992 Aug;18(4):209-15. Abstract
42. Metayer C, Johnson ES, Rice JC. Nested case-control study of tumors of the hemopoietic and lymphatic systems among workers in the meat industry. Am J Epidemiol. 1998 Apr 15;147(8):727-38.Full text Abstract
43. Bethwaite P, McLean D, Kennedy J, et al. Adult-onset acute leukemia and employment in the meat industry: a New Zealand case-control study. Cancer Causes Control. 2001 Sep;12(7):635-43. Abstract
44. Arber DA, Borowitz MJ, Cessna M, et al. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. Arch Pathol Lab Med. 2017 Oct;141(10):1342-93.Full text Abstract
45. National Cancer Comprehensive Network. NCCN guidelines in oncology: acute myeloid leukemia [internet publication].Full text
46. Youn BS, Mantel C, Broxmeyer HE. Chemokines, chemokine receptors and hematopoiesis. Immunol Rev. 2000 Oct;177:150-74. Abstract
47. Anderlini P, Luna M, Kantarjian HM, et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996 Apr;10(4):600-8. Abstract
48. Seymour JF, Pierce SA, Kantarjian H, et al. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994 May;8(5):823-6. Abstract
49. Ravandi F, Cortes J, Estrov Z, et al. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res. 2002 Jul;26(7):643-9.Full text Abstract
50. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969 Oct;71(4):747-52. Abstract
51. Smith ML, Cavenagh JD, Lister TA, et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med. 2004 Dec 2;351(23):2403-7.Full text Abstract
52. Bader J, Miller R. Neurofibromatosis and childhood leukemia. J Pediatr. 1978 Jun;92(6):925-9. Abstract
53. Lan Q, Zhang L, Li G, et al. Hematotoxicity in workers exposed to low levels of benzene. Science. 2004 Dec 3;306(5702):1774-6.Full text Abstract
54. Almond LM, Charalampakis M, Ford SJ, et al. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):263-7. Abstract
55. Siegal T, Benouaich-Amiel A, Bairey O. Neurologic complications of acute myeloid leukemia. Diagnostic approach and therapeutic modalities. Blood Rev. 2022 May;53:100910. Abstract
56. Chean D, Maillard A, Benattia A, et al. Acute respiratory failure in adult patients with acute myeloid leukemia. Expert Rev Respir Med. 2024 Dec;18(12):963-74.Full text Abstract
57. Sobotka LA, Crilley T, Levine E, et al. Acute myelogenous leukemia as a rare cause of duodenal ulcers. ACG Case Rep J. 2019 Jul;6(7):e00153.Full text Abstract
58. Quispe RA, Aguiar EM, de Oliveira CT, et al. Oral manifestations of leukemia as part of early diagnosis. Hematol Transfus Cell Ther. 2022 Jul-Sep;44(3):392-401. Abstract
59. Chen CY, Cheng A, Huang SY, et al. Clinical and microbiological characteristics of perianal infections in adult patients with acute leukemia. PLoS One. 2013;8(4):e60624.Full text Abstract
60. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011 May 12;364(19):1844-54.Full text Abstract
61. Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 Nov;86(5):1327-30. Abstract
62. Ten Cate H, Leader A. Management of disseminated intravascular coagulation in acute leukemias. Hamostaseologie. 2021 Apr;41(2):120-6. Abstract
63. Mehta P, Telford N, Wragg C, et al. Recommendations for laboratory testing of UK patients with acute myeloid leukaemia. Br J Haematol. 2023 Jan;200(2):150-9.Full text Abstract
64. Jenei A, Tzankov A. Diagnostic approach to leukemia cutis : a differential diagnostic step-by-step algorithm. Am J Clin Pathol. 2025 Mar 8;163(3):395-405.Full text Abstract
65. Yamauchi T, Negoro E, Lee S, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013 Sep;33(9):3947-51.Full text Abstract
66. Ferrara F, Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol. 1996 Mar;92(3):627-31. Abstract
67. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions [internet publication].Full text
68. Kulasekararaj A, Cavenagh J, Dokal I, et al. Guidelines for the diagnosis and management of adult aplastic anaemia: a British Society for Haematology guideline. Br J Haematol. 2024 Mar;204(3):784-804.Full text Abstract
69. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012 Mar;47(3):337-41. Abstract
70. Heuser M, Ofran Y, Boissel N, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020 Jun;31(6):697-712.Full text Abstract
71. Sekeres MA, Guyatt G, Abel G, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020 Aug 11;4(15):3528-49.Full text Abstract
72. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1249-59.Full text Abstract
73. Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013 Sep 20;31(27):3360-8. Abstract
74. Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 Jun 18;125(25):3878-85.Full text Abstract
75. Luskin MR, Lee JW, Fernandez HF, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 Mar 24;127(12):1551-8.Full text Abstract
76. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001 Sep 1;98(5):1302-11. Abstract
77. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol. 2011 Mar;152(5):524-42.Full text Abstract
78. Rücker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012 Mar 1;119(9):2114-21.Full text Abstract
79. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020 Aug 13;383(7):617-29.Full text Abstract
80. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46.Full text Abstract
81. Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 Sep 10;36(26):2684-92.Full text Abstract
82. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021 Jul;8(7):e481-91. Abstract
83. Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021 Dec 30;138(26):2753-67.Full text Abstract
84. Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Dec;17(12):1796-803.Full text Abstract
85. Devine SM, Owzar K, Blum W, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (alliance for clinical trials in oncology)/blood and marrow transplant clinical trial network 0502. J Clin Oncol. 2015 Dec 10;33(35):4167-75.Full text Abstract
86. Li Z, Liu Y, Wang Q, et al. Autologous stem cell transplantation is a viable postremission therapy for intermediate-risk acute myeloid leukemia in first complete remission in the absence of a matched identical sibling: a meta-analysis. Acta Haematol. 2019;141(3):164-75.Full text Abstract
87. Venditti A, Piciocchi A, Candoni A, et al. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019 Sep 19;134(12):935-45.Full text Abstract
88. Wei AH, Döhner H, Pocock C, et al. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020 Dec 24;383(26):2526-37.Full text Abstract
89. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 Aug 3;377(5):454-64.Full text Abstract
90. Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019 Feb 21;133(8):840-51.Full text Abstract
91. Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 May 13;401(10388):1571-83. Abstract
92. Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1201-12. Abstract
93. Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020 Sep 10;38(26):2993-3002.Full text Abstract
94. Levis MJ, Hamadani M, Logan B, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024 May 20;42(15):1766-75.Full text Abstract
95. Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol. 2020 Dec 20;38(36):4249-59.Full text Abstract
96. Medicines and Healthcare Products Regulatory Agency. Venetoclax (Venclyxto): updated recommendations on tumour lysis syndrome (TLS). Dec 2021 [internet publication].Full text
97. Roboz GJ, DiNardo CD, Stein EM, et al. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Blood. 2020 Feb 13;135(7):463-71.Full text Abstract
98. Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022 Apr 21;386(16):1519-31.Full text Abstract
99. Food and Drug Administration. FDA warns that symptoms of a serious condition affecting the blood cells are not being recognized with the leukemia medicine Idhifa (enasidenib). Nov 2018 [internet publication].Full text
100. McMahon CM, Canaani J, Rea B, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv. 2019 May 28;3(10):1581-5.Full text Abstract
101. DeWolf S, Tallman MS. How I treat relapsed or refractory AML. Blood. 2020 Aug 27;136(9):1023-32.Full text Abstract
102. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005 Mar 20;23(9):1969-78.Full text Abstract
103. Yanada M, Garcia-Manero G, Borthakur G, et al. Potential cure of acute myeloid leukemia : analysis of 1069 consecutive patients in first complete remission. Cancer. 2007 Dec 15;110(12):2756-60.Full text Abstract
104. Wattad M, Weber D, Döhner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017 Jun;31(6):1306-13. Abstract
105. Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, et al. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review. Ann Hematol. 2018 Jul;97(7):1115-53. Abstract
106. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991 Jul;9(7):1210-4. Abstract
107. Sanz MA, Fenaux P, Tallman MS, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019 Apr 11;133(15):1630-43.Full text Abstract
108. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021 Jun 30;11(6):123.Full text Abstract
109. Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570-80; quiz 1752.Full text Abstract
110. Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015 Sep;2(9):e357-66. Abstract
111. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999 Aug 15;94(4):1192-200.Full text Abstract
112. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocyticleukemia: very long-term results and role of maintenance. Blood. 2011 May 5;117(18):4716-25.Full text Abstract
113. Muchtar E, Vidal L, Ram R, et al. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. Cochrane Database Syst Rev. 2013 Mar 28;(3):CD009594.Full text Abstract
114. de Botton S, Fenaux P, Yee KWL, et al. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023 Feb 1:bloodadvances.202200941.Full text Abstract
115. Norsworthy KJ, Mulkey F, Scott EC, et al. Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis. Clin Cancer Res. 2020 Aug 15;26(16):4280-8.Full text Abstract
116. Stanworth SJ, Estcourt LJ, Powter G, et al; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013 May 9;368(19):1771-80.Full text Abstract
117. Odetola O, Tallman MS. How to avoid early mortality in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):248-53.Full text Abstract
118. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 Oct 20;36(30):3043-54.Full text Abstract
119. Gao L, Zhang Y, Wang S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML ater HSCT: an open-label, multicenter, randomized controlled Trial. J Clin Oncol. 2020 Dec 20;38(36):4249-59.Full text Abstract
120. Geissler K, Koristek Z, Bernal Del Castillo T, et al. Oral Decitabine/cedazuridine vs intravenous decitabine for acute myeloid leukemia: final results of a randomized, crossover, registration-enabling, pharmacokinetics study. Blood 2023;142(suppl 1):1538.
121. Saygin C, Carraway HE. Emerging therapies for acute myeloid leukemia. J Hematol Oncol. 2017 Apr 18;10(1):93.Full text Abstract
122. Roboz GJ, Döhner H, Gobbi M, et al. Results from a global randomized phase 3 study of guadecitabine (G) vs treatment choice (TC) in 815 patients with treatment naïve (TN) AML unfit for intensive chemotherapy (IC) ASTRAL-1 study: analysis by number of cycles. Blood 2019 Nov;134(1 suppl):2591.
123. Wang ES, Goldberg AD, Tallman M, et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML. J Clin Oncol. 2024 May 20;42(15):1776-87.Full text Abstract
124. Oran B, Marin D, Bashir Q, et al. Long-term follow-up of crenolanib maintenance after allogeneic transplantation in newly diagnosed and relapsed FLT3 mutated AML. Blood 2024;144:1497.Full text
125. ClinicalTrials.gov. Flotetuzumab; acute myeloid leukemia; phase 2 [internet publication].Full text
126. Short NJ, Daver N, Dinardo CD, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024 May 1;42(13):1499-1508. Abstract
127. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015 Sep 17;373(12):1136-52. Abstract
128. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003 Dec 15;21(24):4642-9. Abstract
129. National Cancer Institute. Acute myeloid Lleukemia (AML) SEER 5-rear relative survival Rrates, 2015-2021: all stages by sex and age, all races/ethnicities [internet publication].Full text
130. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997 May 1;89(9):3323-9.Full text Abstract
131. Ossenkoppele G, Löwenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015 Jan 29;125(5):767-74.Full text Abstract
132. Rausch C, Rothenberg-Thurley M, Dufour A, et al. Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 11 Apr 2023 [Epub ahead of print].Full text Abstract
133. Kelaidi C, Chevret S, De Botton S, et al. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol. 2009 Jun 1;27(16):2668-76. Abstract
134. Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. 2012 Jun 13;(6):CD008238. Abstract
135. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol. 2010 Jun 10;28(17):2914-24. Abstract
Use of this content is subject to our disclaimer